Integrated drug discovery and development expertise
Cross-disciplinary scientific and operational expertise spanning therapy areas, modalities, development stages and disciplines.
The stages of drug development are not universal. The pathway from target selection to first-in-human looks fundamentally different depending on the modality.
Early-stage drug development demands deep specialised knowledge, rigorously and effectively coordinated across disciplines to move programmes forward.
Linchpin integrates cross-disciplinary scientific and operational expertise, helping biotech companies and investors navigate development from concept through preclinical stages and into early clinical execution.
Our model
From integrated expertise to programme execution
Linchpin’s model is built on four core capabilities:
Independent scientific judgement
Integrated
expertise
Strategy
and execution
Embedded
partnership
These are not abstract principles. They are applied through deep scientific and operational expertise across early-stage drug development.
Multiple dimensions
Navigating drug development across stages, modalities and disciplines
Early-stage drug development is not linear. It requires coordination across multiple dimensions:
- Therapy areas
- Therapeutic modalities
- Development stages
- Scientific and operational disciplines
Linchpin integrates expertise across these dimensions ensuring alignment, continuity, and forward momentum across the development pathway.
Across therapy areas
Rather than operating within narrow silos, Linchpin applies cross-therapy area expertise to support robust and adaptable development strategies.
Discover Linchpin’s cross-therapy area expertise.
- Oncology
- Immunology and inflammation
- CNS and neurodegeneration
- Metabolic disease
- Cardiovascular and rare disease
Across therapeutic modalities
Linchpin helps teams evaluate the full modality landscape before committing to a development path, combining target biology assessment, clinical precedent analysis and operational feasibility into a clear, evidence-based recommendation.
Discover Linchpin’s expertise across therapeutic modalities.
- Small molecules and peptides
- Biopharmaceuticals: mAbs, biologics and ADCs
- Oligonucleotides and RNA therapeutics
- Cell and gene therapy
- Targeted degraders and covalent molecules
Across development stages: drug discovery to clinic
The stages of drug development are not universal. The pathway from target selection to First-in-Human looks fundamentally different depending on the modality. Linchpin’s consultants understand these differences and navigate them. Linchpin supports programmes across the full early-stage drug development lifecycle:
Discover Linchpin’s drug development stage-specific expertise by modality.
This ensures continuity from early scientific insight through to coordinated programme delivery.
- Discovery and target validation
- Lead identification and optimisation
- Preclinical development
- IND-enabling studies
- Early clinical strategy and execution
Across scientific and operational disciplines
Linchpin integrates expertise across core disciplines required for early-stage drug development.
Explore Linchpin’s expertise from therapeutic strategy through DMPK, toxicology and safety assessment to business development support.
This expertise is deployed in a coordinated way, aligned to programme priorities, milestones and investor expectations.
- Therapeutic and platform strategy
- Target identification and validation
- Medicinal chemistry and molecular design
- Translational pharmacology and disease biology
- DMPK, toxicology and safety assessment
- CMC and manufacturing strategy
- Early clinical development and execution
- Operations and programme management
- Business development and investment support
Put this expertise on your programme
Whether you need targeted expertise or integrated programme delivery, Linchpin provides the scientific and operational capability to help you navigate early-stage drug development and move forward with clarity and confidence.